A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

Summary

A study to evaluate the safety and tolerability of AMG 119 in adult subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate cell dose.

Timeline

Start

2018-09-10

Primary completion

2028-01-14

Completion

2028-01-14

Outcome

Outcome not reported

Stopped (Enrollment): “Study on enrollment hold, may potentially resume. No active subjects on trial.”

Publications

• Background Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2.

Drugs

Indications